Skip to content

Corvus Pharmaceuticals

US · CRVS #3339 by market cap Listed 2016
9.67 -0.34 -3.40%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 9.98 -0.30%
After-hours 9.67 0.00%
16.209.389.672026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CRVS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -9.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 21.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -32.6% Better than 12%
Return on invested capital -37.1% Better than 8%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.1% Better than 15%
6-month return -23.3% Better than 24%
12-month return (ex latest month) 24.3% Better than 64%
Distance below 52-week high 64.1% Better than 8%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.2x Better than 89%
Debt to assets 1.3% Better than 91%
Interest coverage -2,881.7x Better than 1%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 182.6% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.12%
1M -5.47%
3M -32.52%
6M -20.67%
YTD +25.58%
1Y +13.63%
3Y +544.67%
5Y +176.29%

Key statistics

Price & volume

Prev close
10.01
Open
9.84
Day range
9.56 - 10.04
Avg price
9.70
Volume
927.52K
Turnover
9.00M
Amplitude
4.85%
52-week range
6.39 - 26.95

Valuation

P/E
-18.25
P/E (TTM)
-13.43
P/B
3.91
EPS
-0.53
Net profit
-44.71M
Net assets
208.35M

Share structure

Market cap
815.69M
Float cap
706.07M
Shares out
84.35M
Float shares
73.02M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-03-23
52-week range 16% of range
6.39 26.95

64.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.09M net over the window

Short interest

Shares short
17.76M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Corvus Pharmaceuticals (CRVS)?

Corvus Pharmaceuticals last traded at 9.67. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Corvus Pharmaceuticals's market cap?

About 815.69M.

What is the P/E ratio of Corvus Pharmaceuticals?

The trailing twelve-month P/E is -13.43. The Valuation tab shows it against the stock's own five-year range.

Does Corvus Pharmaceuticals pay a dividend?

Corvus Pharmaceuticals does not currently pay a regular dividend.

Is Corvus Pharmaceuticals a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 27.33, which implies 182.6% upside from the current price. This is not investment advice.

What is Corvus Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Corvus Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Corvus Pharmaceuticals discussion 0 comments

Add a comment